Company Overview and News

 
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-10-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ESRT

 
 
REIT Model Portfolio: July 2018 Update

2018-08-01 seekingalpha
Given enough time, I expect my portfolio will outperform since I focus on companies that are fundamentally strong, oversold, minimally shorted by investors, and have had their dividend stress tested.
IYR AMID DEI EQIX ESS HR ESRT

 
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-07-25 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRT

 
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-07-25 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRT

7
Mid-Year REIT Market Update

2018-07-05 seekingalpha
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
BPY DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC AVB VNO EQIX FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD KRLP OFC IRT REXR DLR LPT WRI ESRT

17
Office REITs: Jobs, Jobs, Jobs

2018-06-05 seekingalpha
Despite a record 92 consecutive months of job growth, office REITs have yet to fully recover from the previous recession. The sector has been a perennial underperformer since 2007.
DEI EQC EQCO PGRE BXP ESRT

244
You Say 'Vornado', I Say 'Vornado'

2018-05-31 seekingalpha - 2
Maybe it’s a southern thing, because when I’m in Manhattan, my fellow analysts pronounce it Vor-nah-to.
WFCNP UE.WI BXP STWD.WI BAC UBS MS AB WFC C UE JBGS MSFT STWD SLG ULSGF ESRT

1
ESRT / Empire State Realty Trust, Inc. FORM 8-K (Current Report)

2018-05-22 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRT

 
ESRT / Empire State Realty Trust, Inc. / COHEN & STEERS INC - null (Passive Investment)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.9) Empire State Realty Trust, Inc. ----------------------------------- (Name of Issuer) Common Stock ----------------- (Title of Class of Securities) 292104106 ---------
ESRT

1
ESRT / Empire State Realty Trust, Inc. / COHEN & STEERS INC - null (Passive Investment)

2018-05-10 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.9) Empire State Realty Trust, Inc. ----------------------------------- (Name of Issuer) Common Stock ----------------- (Title of Class of Securities) 292104106 ---------
ESRT

 
25
New Strong Sell Stocks for April 27th

2018-04-27 zacks
Apogee Enterprises, Inc. (APOG - Free Report) is a designer of glass products and services. The Zacks Consensus Estimate for its current year earnings has been revised 12% downward over the last 30 days.
GIS FBC B ESRT APOG

 
Empire State Realty Trust, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-04-26 seekingalpha
The following slide deck was published by Empire State Realty Trust, Inc. in conjunction with their 2018 Q1 earnings call.
ESRT

28
Empire State Realty Trust's (ESRT) CEO Tony Malkin on Q1 2018 Results - Earnings Call Transcript

2018-04-26 seekingalpha
Empire State Realty Trust, Inc. (NYSE:ESRT) Q1 2018 Earnings Conference Call April 26, 2018 8:30 AM ET
WFC WFCNP ESRT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 292104106